Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
Product Unit Size | Cost | Quantity | Stock |
---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
Cas No. | 1258595-14-0 |
---|---|
Purity | ≥99% |
Formula | C29H32F2N3O7P |
Formula Wt. | 603.56 |
IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
Synonym | LHC165 |
Appearance | Pale yellow powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
FLT3, PDGFR inhibitor.
Piroxicam prodrug, NSAID; COX-1/2 inhibitor.
Rapamycin impurity
Endogenous peptide; FPRL1/2 agonist.
Antimicrobial peptide found in bee and wasp ven...
Cholesterol ester transfer protein inhibitor.
Phytohormone
M4 mAChR agonist, 5-HT1A partial agonist, M1/2/...
Heterocyclic derivative of cysteine, alters pro...
Endogenous opioid peptide derived from the β-c...
Bisphosphonate; inhibits transfer of farnesyl p...
Endogenous thyroid hormone T4.
Endogenous peptide, involved in hormone regulat...
IGF-1R inhibitor.
Fluoroquinolone; topoisomerase IV and bacterial...
PAK4 inhibitor.
Peptide fragment of HER2/neu/erbB2 receptor.
Naturally-ocurring neurtral cyclic ionophore, m...
Alters intracellular glutathione levels.
CDK9 inhibitor.